glp-1 obesity drugs pipeline Transforming obesity: The advancement of multi-receptor drugs: Cell This new article analyses the
Description
Accordingly, dulaglutide, liraglutide and semaglutide are indicated to reduce cardiovascular risk in people with type 2 diabetes
They also aid in overcoming barriers to weight loss, such as constant hunger or cravings, which can derail even the most well-intentioned diet plans
Mol Metab 2017;6:4406.ArticlePubMedPMC 60
Also, widespread awareness among both clinicians and patients drives the expansion
Starting at the lowest dose and increasing the dose gradually over time may help to minimize side effects
